Biocon Ltd (BIOCON) is listed on the NSE in the Pharmaceuticals sector, Pharmaceuticals & Biotechnology industry. Market capitalisation: 69262.00 Cr. Figures below are as reported and are shown with their source and date.
Biocon Ltd. is a holding company, which engages in the manufacture, research, and development of therapeutic drugs. The company is headquartered in Bangalore, Karnataka and currently employs 3,408 full-time employees. The company went IPO on 2004-04-17. Its segment includes Generics, Biosimilars, Novel Biologics and Research Services. The company has developed and commercialized novel biologics, biosimilars, and complex small molecule active pharmaceutical ingredients (APIs) in India and several key global markets, as well as Generic Formulations in the United Sates, Europe and key emerging markets. Its API portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology and other key products. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. The company has over five facilities across Bangalore, Hyderabad and Visakhapatnam in India. Its API manufacturing facilities leverage complex technology platforms that range from microbial fermentation, chromatographic purification, chemical synthesis, peptide synthesis and HPAPIs.
Source: finedge · as of 2026-09-29
Last close (₹): 330.3
Source: quantro_screener_metrics_job · as of 2026-10-22
Source: quantro_screener_metrics_job · as of 2026-10-23
| Year ended | Revenue (₹ Cr) | PAT (₹ Cr) | EPS (₹) |
|---|---|---|---|
| Mar 2026 | 16,927 | 385.6 | 2.38 |
| Mar 2025 | 15,261.7 | 1,013.3 | 8.44 |
| Mar 2024 | 14,755.7 | 1,022.5 | 8.52 |
| Mar 2023 | 11,174.2 | 462.7 | 3.85 |
| Mar 2022 | 8,184 | 648.4 | 5.4 |
Source: finedge · as of 2026-07-21
Source: finedge · as of 2026-03-31
Source: quantro_company_profiles · as of 2026-10-23
Source: nse · as of 2026-10-05
Figures computed 2026-10-23.